Nanoform has announced the completion and final results of its clinical study.
The primary, secondary and optional exploratory objectives of the study were all met.
The results show that Nanoform’s CESS technology enabled development of a fast-acting piroxicam immediate release (IR) tablet formulation with more rapid absorption and improved drug delivery performance in comparison to a standard reference IR tablet, states the company in a press release.
Nanoform has now received the final clinical study report on the pharmacokinetic (PK) study results related to its Phase 1, single-center, part crossover, open-label, partially-randomized study designed to evaluate the PK profile of piroxicam following administration of nanoformed oral IR piroxicam tablets and IR reference products in healthy subjects (UNICORN).
